An alternate approach to the production of radioisotopes for nuclear medicine applications.
暂无分享,去创建一个
J. D'auria | T. Ruth | S. Lapi | K. Ladouceur | P. Schmor | Roderich Keller
[1] P. Wallner,et al. The new golden era for radioimmunotherapy: not just for lymphomas anymore. , 2013, Cancer control : journal of the Moffitt Cancer Center.
[2] F. Theil,et al. Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. , 2011, Therapeutic delivery.
[3] T. Ruth,et al. The MoRe project: an alternative route to the production of high specific activity 99Mo , 2010 .
[4] J. Kotzerke,et al. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases , 2007, Nuclear medicine communications.
[5] N. Shuke,et al. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart. , 2005, Cancer letters.
[6] I. Brown. The Physics and Technology of Ion Sources: BROWN:ION SOURCES 2ED O-BK , 2004 .
[7] W. Oyen,et al. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] B. R. Nielsen,et al. High‐current ion beams of metallic elements , 1990 .
[9] P. Spädtke,et al. CORDIS—an improved high-current ion source for gases , 1984 .
[10] C. P. Keim. Electromagnetic Separation of Stable Isotopes , 1952 .